The reason we selected the JAK3-INSL3 fusion transcript for validation is because of its high incidences and constitutive JAK3 activation implicated in the pathogenesis of CTCL. The gene discussed is INSL3; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.